NASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free TELO Stock Alerts $6.86 +0.07 (+1.03%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$5.90▼$6.8750-Day Range$4.83▼$9.1452-Week Range$4.76▼$20.72Volume23,964 shsAverage Volume58,189 shsMarket Capitalization$203.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media Get Telomir Pharmaceuticals alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Telomir Pharmaceuticals Stock (NASDAQ:TELO)Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Read More TELO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TELO Stock News HeadlinesApril 26, 2024 | americanbankingnews.comTelomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 2.4%April 16, 2024 | globenewswire.comTelomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 2, 2024 | globenewswire.comTelomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024March 29, 2024 | globenewswire.comUPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesMarch 26, 2024 | globenewswire.comTelomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in CaninesMarch 22, 2024 | globenewswire.comTelomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26thMarch 14, 2024 | globenewswire.comTelomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal ScienceApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 7, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 7, 2024 | globenewswire.comTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore ConferenceMarch 5, 2024 | globenewswire.comMichael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age ReversalSee More Headlines Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)7/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CUSIPN/A CIK1971532 Webtelomirpharma.com Phone(737)-289-0835FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares29,610,000Free FloatN/AMarket Cap$203.27 million OptionableN/A BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Christopher C. Chapman Jr. (Age 71)M.D., Co-Founder, Chairman & CEO Mr. Nathen Fuentes CPA (Age 41)CFO, Treasurer, & Secretary Key CompetitorsLifecore BiomedicalNASDAQ:LFCRG1 TherapeuticsNASDAQ:GTHXGeneration BioNASDAQ:GBIOZevra TherapeuticsNASDAQ:ZVRARigel PharmaceuticalsNASDAQ:RIGLView All Competitors TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed in 2024? Telomir Pharmaceuticals' stock was trading at $5.00 at the beginning of the year. Since then, TELO stock has increased by 37.3% and is now trading at $6.8650. View the best growth stocks for 2024 here. When is Telomir Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024. View our TELO earnings forecast. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering on Friday, February 9th 2024. The company issued 1,000,000 shares at a price of $7.00 per share. Kingswood Investments served as the underwriter for the IPO. When did the company's quiet period expire? Telomir Pharmaceuticals' quiet period expired on Wednesday, March 20th. Telomir Pharmaceuticals had issued 1,000,000 shares in its IPO on February 9th. The total size of the offering was $7,000,000 based on an initial share price of $7.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TELO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
